[Marseille welcomes the FSHD Society International Research Conference].
暂无分享,去创建一个
[1] W. Wright,et al. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy , 2019, Experimental Neurology.
[2] Jay J. Han,et al. Longitudinal study of upper extremity reachable workspace in fascioscapulohumeral muscular dystrophy , 2019, Neuromuscular Disorders.
[3] M. Lamers,et al. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain , 2019, Journal of Medical Genetics.
[4] S. Tapscott,et al. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy , 2019, The Journal of Pharmacology and Experimental Therapeutics.
[5] G. Siciliano,et al. Phenotype may predict the clinical course of facioscapolohumeral muscular dystrophy , 2019, Muscle & nerve.
[6] S. Tapscott,et al. MRI‐informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD , 2018, Human molecular genetics.
[7] F. Magdinier,et al. Analysis of the 4q35 chromatin organization reveals distinct long-range interactions in patients affected with Facio-Scapulo-Humeral Dystrophy , 2018, bioRxiv.
[8] B. Engelen,et al. 225th ENMC international workshop: A global FSHD registry framework, 18–20 November 2016, Heemskerk, The Netherlands , 2017, Neuromuscular Disorders.